{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"The evaluation of the rate of conversion in Complete Remission with daratumumab maintenance therapy for patients in Partial Remission after the induction.\n\nWith this endpoint it will be measured the number of responses that will be converted from Partial Remission (PR) to Complete Remission (CR) in those patients that after induction therapy continued the treatment with the maintenance therapy.","groups":[{"description":"Daratumumab in combination with Gemcitabine, Dexamethasone and Cisplatin (D-GDP) in patients with relapsed/refractory CD38 positive peripheral T-cell lymphoma not otherwise specified (PTCL-NOS), angioimmunoblastic T-cell lymphoma (AITL) and other nodal lymphomas of TFH cell origin.","id":"OG000","title":"One Arm"}],"populationDescription":"Due the early interruption of the trial, this end point was not evaluated. So, data were not collected.","reportingStatus":"POSTED","timeFrame":"The endpoint will be assessed at each restaging through study completion, up to 26 months.","title":"Role of Daratumumab Maintenance CR vs PR","type":"OTHER_PRE_SPECIFIED"}